[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652305":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":44,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Bagcilar Training and Research Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment-naive OAB cohort",null,"Treatment-naive adult women with overactive bladder in whom mirabegron 50 mg once daily is initiated by physician decision within routine clinical care. Baseline assessment includes a 3-day voiding diary, the OAB-q short form, routine urodynamic evaluation, and a standardized complete blood count; treatment response is assessed at 3 months.",[13],"Drug: Mirabegron (beta3-adrenoceptor agonist)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Mirabegron (beta3-adrenoceptor agonist)","Mirabegron 50 mg orally once daily, initiated and managed by the treating physician as part of routine clinical care. The drug is not assigned by the study protocol; the study observes patients in whom this treatment has been started within standard practice.",[9],[21],{"name":22,"affiliation":5,"role":23},"Özgür Aslan, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+90 5384243325","ozgraslan92@gmail.com",[30],{"facility":5,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":10,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Istanbul","Bagcilar","34200","Turkey (Türkiye)",{"type":36,"coordinates":37},"Point",[38,39],28.94966,41.01384,{"lat":39,"lon":38},[42,43],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"özgür aslan","Specialist Physician","100652305","predictive-value-of-inflammatory-biomarkers-for-mirabegron-response-in-women-with-overactive-bladder-100652305",false,"NCT07773532","Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder","Predictive Capacity of Baseline Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index for Mirabegron Treatment Response in Women With Overactive Bladder: A Prospective Cohort Study","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Overactive bladder symptoms for at least 3 months\n* Mirabegron 50 mg planned by physician decision within routine care\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation)\n* Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection\n* Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease)\n* Active malignancy or cancer treatment within the last 5 years\n* Use of systemic glucocorticoids within the last 4 weeks, or chronic NSAID or immunosuppressive use\n* Conditions affecting lower urinary tract function other than OAB (neurogenic bladder, urinary tract stones, history of pelvic radiotherapy or bladder surgery, pelvic organ prolapse stage 3 or higher, or stress-predominant mixed urinary incontinence)\n* Known diagnosis of hematologic disease, anemia (Hb\\\u003C9), or platelet disorder (PLT\\\u003C100.000 or \\>600.000)\n* Significant renal or hepatic impairment (eGFR below 30 mL\u002Fmin\u002F1.73 m2, or Child-Pugh class B or C)\n* Uncontrolled hypertension (180\u002F110 mmHg or higher) or any other contraindication to mirabegron\n* Pregnancy or lactation\n* Major surgery or trauma within the last 3 months\n* Cognitive or functional inability to complete the voiding diary","FEMALE","18 Years",{"count":57,"type":58},115,"ESTIMATED","OBSERVATIONAL","Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.",[62],"Overactive Bladder (OAB)",[64,65,66,67,68,69,70,71,72,73,74],"Overactive Bladder","Adrenergic beta 3 Receptor Agonists","Inflammation","Biomarkers","Blood Cell Counts","Neutrophil-to-Lymphocyte Ratio","Platelet-to-Lymphocyte Ratio","Systemic Immune-Inflammation Index","NLR","PLR","SII","NOT_YET_RECRUITING","2026-08-18",{"date":78,"type":79},"2026-08-19","ACTUAL",{"date":81,"type":58},"2026-10-01",{"date":83,"type":58},"2027-11-01",{"name":5,"class":6},1]